Rebecca Robertson, a director at Ceribell, Inc. (NASDAQ: CBLL), disposed of 827 shares of the company's common stock on March 3, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares changed hands at $17.80 each, producing a total sale amount of $14,720.
Following the transaction, Robertson's direct holdings in Ceribell stand at 18,749 shares. The sale was carried out under a Rule 10b5-1 trading plan, the filing states.
The share sale comes against a mixed market backdrop for Ceribell. The stock has fallen 8.4% over the past week, even as it remains more than 50% higher compared with its price six months ago. Independent analysis cited in filings suggests the stock appears priced above its Fair Value, while sell-side analysts continue to set price targets in a $24 to $32 per share range.
Corporate and product developments at Ceribell have been active in recent weeks. The company announced that the U.S. Food and Drug Administration granted Breakthrough Device Designation to its Large Vessel Occlusion, or LVO, stroke detection monitor. The device combines Ceribell's existing electroencephalography, or EEG, hardware with an AI-driven algorithm intended to support early stroke detection in hospital settings. The company and filings note that this designation could position the system as a first point-of-care EEG technology for LVO stroke detection and monitoring.
On the analyst front, BTIG has reiterated a Buy rating and maintained a $30 price target for Ceribell, citing expectations for nearly 30% year-over-year revenue growth for 2026.
There have also been changes in Ceribell's governance and operations. Lucian Iancovici resigned from the company's board of directors and its related committees, with reports indicating no disagreements with the company over its operations. Separately, Ceribell extended its office leases in Sunnyvale, California, through January 2028, reflecting ongoing operational commitments.
Context and takeaway - The insider sale was modest in size and executed under an established trading plan. It coincides with important regulatory and commercial milestones for the company, including the FDA Breakthrough Device designation for its LVO stroke monitor, continued analyst coverage with bullish price targets, a board resignation announced without cited disputes, and a lease extension demonstrating continued operational presence in Sunnyvale.
Note: Where filings or commentary in this article reference valuation analysis or analyst price targets, those points are drawn from the company's public filings and analyst reports referenced in regulatory disclosures.